
    
      Patients with major depressive disorder who meet all of the eligibility criteria will be
      randomly assigned to receive twice daily doses of either placebo or PRX-00023. Study drug
      will be taken for up to approximately 9 weeks. Patients will have periodic office visits for
      the purpose of monitoring safety and tolerability, as well as efficacy assessments.
    
  